Other than MET amplification, some resistant cancers showed unexpected genetic alterations including mutations in PIK3CA and amplification of HER2. Aberrant activation of PI3K/AKT signaling in the presence of EGFR kinase inhibitor can result in drug resistance (Engelman and Janne, 2008). The gene discussed is MET; the disease is cancer.